UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by a Party other than the Registrant \Box

Filed by the Registrant ⊠

Che	eck the appropriate box:
	Preliminary Proxy Statement
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
	Definitive Proxy Statement
\times	Definitive Additional Materials
	Soliciting Material Pursuant to §240.14a-12
	PRAXIS PRECISION MEDICINES, INC. (Exact name of registrant as specified in its charter)
	(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Pay ⊠	(Name of Person(s) Filing Proxy Statement, if other than the Registrant) oment of Filing Fee (Check the appropriate box): No fee required.
_	oment of Filing Fee (Check the appropriate box):



PRAXIS PRECISION MEDICINES, INC.

2022 Annual Meeting Vote by May 25, 2022 11:59 PM ET



D82758-P71208

PRAXIS

You invested in PRAXIS PRECISION MEDICINES, INC. and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholders meeting to be held on May 26, 2022.

Get informed before you vote

View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 12, 2022. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #

Smartphone users

Point your camera here and vote without entering a control number





Vote Virtually at the Meeting*

May 26, 2022 9:00 a.m., Eastern Time

Virtually at: www.virtualshareholdermeeting.com/PRAX2022

^{*}Please check the meeting materials for any special requirements for meeting attendance

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming stockholders meeting. More complete proxy materials, which contain important information, are available on the Internet or by mail. Please follow the instructions on the reverse side to access and review the complete proxy materials before voting, and to vote these important matters.

1b. Merit Cudkowicz, M.D. 1c. Stefan Vitorovic 2. To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022. 3. To approve on a non-binding advisory basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2022 Annual Meeting pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion. 4. The second of the secon	For
Nominees: 1a. Jeffrey Chodakewitz, M.D. 1b. Merit Cudkowicz, M.D. 1c. Stefan Vitorovic 2. To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022. 3. To approve on a non-binding advisory basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2022 Annual Meeting pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion. 4. To approve on a non-binding advisory basis the frequency of future advisory votes on the compensation of the Company's named executive officers.	
 1a. Jeffrey Chodakewitz, M.D. 1b. Merit Cudkowicz, M.D. 1c. Stefan Vitorovic 2. To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022. 3. To approve on a non-binding advisory basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2022 Annual Meeting pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion. 4. To approve on a non-binding advisory basis the frequency of future advisory votes on the compensation of the Company's named executive officers. 3. NOTE: Also includes authorization to transact any other business as may properly come before the meeting or any 	
1b. Merit Cudkowicz, M.D. 1c. Stefan Vitorovic 2. To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022. 3. To approve on a non-binding advisory basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2022 Annual Meeting pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion. 4. To approve on a non-binding advisory basis the frequency of future advisory votes on the compensation of the Company's named executive officers. NOTE: Also includes authorization to transact any other business as may properly come before the meeting or any	
 1c. Stefan Vitorovic To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022. To approve on a non-binding advisory basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2022 Annual Meeting pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion. To approve on a non-binding advisory basis the frequency of future advisory votes on the compensation of the Company's named executive officers. 	
 To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022. To approve on a non-binding advisory basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2022 Annual Meeting pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion. To approve on a non-binding advisory basis the frequency of future advisory votes on the compensation of the Company's named executive officers. NOTE: Also includes authorization to transact any other business as may properly come before the meeting or any	For
fiscal year ending December 31, 2022. 3. To approve on a non-binding advisory basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2022 Annual Meeting pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion. 4. To approve on a non-binding advisory basis the frequency of future advisory votes on the compensation of the Company's named executive officers. NOTE: Also includes authorization to transact any other business as may properly come before the meeting or any	For
Company's proxy statement for the 2022 Annual Meeting pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion. 4. To approve on a non-binding advisory basis the frequency of future advisory votes on the compensation of the Company's named executive officers. NOTE: Also includes authorization to transact any other business as may properly come before the meeting or any	For
Company's named executive officers. NOTE: Also includes authorization to transact any other business as may properly come before the meeting or any	For
NOTE: Also includes authorization to transact any other business as may properly come before the meeting or any adjournment thereof.	Years

D82759-P71208